Latest Clinical Trials News

Page 8 of 140
Orthocell’s flagship Remplir nerve-repair product gained ground in the US and Thailand during the September quarter, even as total revenue slipped from the June period. The company reported A$39 million in available funds and said it does not currently expect to raise additional capital.
Ada Torres
Ada Torres
22 Oct 2026
Arovella Therapeutics has received a $4.03 million FY2026 R&D tax refund, giving the clinical-stage biotech additional cash as it advances its lead therapy ALA-101 towards first-patient dosing. The payment arrives without any accompanying clinical data or disclosed update to the company’s cash runway.
Ada Torres
Ada Torres
22 Oct 2026
Invion has secured two financing arrangements that could cover up to approximately 85% of its clinical trial costs, providing support for its skin cancer and planned anogenital cancer programs. The funding comes with potential dilution, 16% interest and conditions that leave the actual amount available dependent on drawdowns and R&D tax refunds.
Victor Sage
Victor Sage
21 Oct 2026
Telix reported US$245 million in unaudited third-quarter revenue, with Precision Medicine sales up 30% and full-year revenue and other income still expected to exceed US$1 billion. The quarter also advanced the proposed US$1.65 billion ITM merger, added FDA-approved Pixclara to the commercial portfolio and narrowed the R&D spending range.
Ada Torres
Ada Torres
21 Oct 2026
BPH Energy’s latest quarter puts its portfolio risks in sharp relief: Advent is appealing the PEP11 ruling while another subsidiary remains in voluntary administration. BPH ended September with $1.127 million in cash, but deployed $972,000 in loans to investees during the quarter.
Victor Sage
Victor Sage
21 Oct 2026
Recce Pharmaceuticals says a review of blinded Phase 3 data for its RECCE 327 Gel showed strong efficacy and a positive safety profile. An independent committee is expected to assess unblinded data from 75 patients as soon as mid-November, while recruitment continues.
Ada Torres
Ada Torres
20 Oct 2026
Percheron Therapeutics has secured a funded path towards a Vanderbilt Health-led HMBD-002 trial in high-risk AML and MDS, while ending September with $4.875 million in cash. The biotechnology company also installed a new chief executive and began a preclinical combination study with Invion.
Ada Torres
Ada Torres
20 Oct 2026
Actinogen Medical says its pivotal XanaMIA Alzheimer’s trial remains on course for topline results in November after the final patient visit was completed. The company also reported $15.9 million in cash, a further $5.3 million from option funding and a projected runway into late 2027 or 2028, assuming future trials are substantially partner-funded.
Ada Torres
Ada Torres
19 Oct 2026
Acrux has received clearer FDA guidance for Phase III trials of its female testosterone spray, including potential three-year data exclusivity if the product reaches submission. The company also reported positive September-quarter operating cash flow, but that result was largely driven by a $1.977 million R&D tax rebate and Acrux says it is still pursuing funding for the clinical programme.
Victor Sage
Victor Sage
19 Oct 2026
Nyrada has moved its PROTECT-MI heart-attack trial into active recruitment, with four hospitals open and three patients dosed. The biotech also reported supportive US FDA feedback, encouraging preclinical oncology data and AU$13.72 million in cash after a AU$12 million placement.
Ada Torres
Ada Torres
19 Oct 2026
ECS Botanics has delivered a fifth consecutive quarter of positive operating cash flow, while branded sales and international expansion continue to reshape the business. The next test is whether planned UK and Polish launches can convert into recurring revenue.
Ada Torres
Ada Torres
19 Oct 2026
Cryosite delivered record first-quarter results, with revenue up 17% to $4.6 million and EBITDA rising 31% to $1.3 million. The more consequential test now sits with the TGA, which has audited the company’s Auburn facility as part of a potential licence expansion.
Victor Sage
Victor Sage
19 Oct 2026

Browse the archive

Full archive